[go: up one dir, main page]

WO2013192367A1 - Traitement d'une tumeur neuroendocrine - Google Patents

Traitement d'une tumeur neuroendocrine Download PDF

Info

Publication number
WO2013192367A1
WO2013192367A1 PCT/US2013/046690 US2013046690W WO2013192367A1 WO 2013192367 A1 WO2013192367 A1 WO 2013192367A1 US 2013046690 W US2013046690 W US 2013046690W WO 2013192367 A1 WO2013192367 A1 WO 2013192367A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
compound
formula
neuroendocrine tumor
refractory
Prior art date
Application number
PCT/US2013/046690
Other languages
English (en)
Inventor
Samit Hirawat
Alessandro Riva
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2013192367A1 publication Critical patent/WO2013192367A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a method for treating a neuroendocrine tumor, particularly pancreatic neuroendocrine tumor, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, alone or in combination with at least one therapeutic agent, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor; uses of said compounds for the preparation of a medicament for use in the treatment of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor; uses of said compound for treating said disease; and related pharmaceutical compositions and pharmaceutical package thereof.
  • Neuroendocrine tumors are a heterogeneous group of malignancies that can arise from neuroendocrine cells throughout the body. These tumors are classically divided into two groups: functioning (secreting hormones resulting in symptoms) and non-functioning (non- secreting). An annual incidence of neuroendocrine tumors in the United States is 5.25 cases per 100,000 population. The overall incidence of this disease appears to be increasing, probably due to improved diagnostic techniques (Howlader et al, J. Natl Cancer Inst. 102(20): 1584-98 (Oct 20, 2010)).
  • Pancreatic NET specifically arises from the pancreatic islets of Langerhans and is a rare malignancy. pNETs constitute a distinct subgroup of NETs characterized by a different genetic profile, more aggressive clinical evolution, and a different pattern of response to cytotoxic chemotherapy. The overall incidence of pNET is less than 1 case per 100,000 per year and it accounts for 9% of all NETs. Pancreatic NET accounts for less than 2% of all digestive malignant tumors and less than 1 % of endocrine tumors. Since pNET can initially be slow- growing and indolent, patients tend to present for treatment at a late stage with advanced disease.
  • PI3K phosphatidylinositol 3-kinase
  • mTOR mammalian target of rapamycin pathway plays a central role in cell metabolism.
  • PI3K is activated by growth factors, cytokines, and other stimulatory factors in association with their receptors. Activated PI3K in turn initiates signaling transduction to Akt-mTOR and leads to regulation of cell growth, proliferation, and apoptosis.
  • mTOR modulates translation of specific mRNAs via the regulation of the phosphorylation state of several different translation proteins, mainly 4E-PB1 , P70S6K (p70S6 kinase 1 ) and eEF2. Dysregulation of the PI3K/ mTOR pathway is widely seen in different types of human cancers, including neuroendocrine tumors.
  • Everolimus an mTOR inhibitor also known as Afinitor®, has been recently approved by FDA and EMA for the treatment of advanced pNET based on the RADIANT-3 study. Although everolimus provides clinical benefit for patients with pNET, both de novo and acquired resistance to this agent exists. There continues to be a need for treatment for patients suffering from neuroendocrine tumors, particularly pancreatic neuroendocrine tumors, resistant or refractory to treatment with at least one mTOR inhibitor.
  • the dual phosphatidylinositol 3-kinase inhibitor and mTOR inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof is effective for the treatment of a neuroendocrine tumor, particularly pancreatic neuroendocrine tumor, resistant to treatment with at least one mTOR inhibitor.
  • the present invention relates to a method for treating a neuroendocrine tumor comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, alone or in combination with at least one additional therapeutic compound, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to a method for inhibiting growth of a neuroendocrine tumor, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to a method for inducing neuroendocrine tumor regression, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to a method for preventing metastatic spread of neuroendocrine tumors or for preventing or inhibiting growth of micrometastasis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in inhibiting growth of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in inducing regression of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in preventing metastatic spread of neuroendocrine tumors or for preventing or inhibiting growth of micrometastasis, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for treating a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for inhibiting growth of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for inducing regression of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for preventing metastatic spread of neuroendocrine tumors or for preventing or inhibiting growth of micrometastasis, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to any of the methods or uses above wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered or used in combination with at least one additional therapeutic compound,
  • the present invention further relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with at least one pharmaceutically acceptable excipient for use in the treatment of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to a pharmaceutical package comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and instructions for administration for the treatment of a neuroendocrine tumor, particularly pNET, resistant or refractory to treatment with at least one mTOR inhibitor; Detailed Description of the Invention
  • the present invention relates to a method for treating a neuroendocrine tumor comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, alone or in combination with at least one additional therapeutic compound, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • a phosphatidylinositol 3-kinase inhibitor or "PI3K inhibitor” is defined herein to refer to a compound which targets, decreases or inhibits PI 3-kinase.
  • PI 3-kinase activity has been shown to increase in response to a number of hormonal and growth factor stimuli, including insulin, platelet-derived growth factor, insulin-like growth factor, epidermal growth factor, colony-stimulating factor, and hepatocyte growth factor, and has been implicated in processes related to cellular growth and transformation.
  • mammalian target of rapamycin inhibitor or “mTOR inhibitor” is defined herein to refer to compounds which target, decrease or inhibit the activity/function of mammalian target of rapamycin (mTOR) kinase.
  • pharmaceutical composition is defined herein to refer to a mixture or solution containing at least one therapeutic agent to be administered to a subject, e.g., a mammal or human, in order to prevent or treat a particular disease or condition affecting the subject thereof.
  • pharmaceutically acceptable is defined herein to refer to those compounds, materials, compositions and/or dosage forms, which are, within the scope of sound medical judgment, suitable for contact with the tissues a subject, e.g., a mammal or human, without excessive toxicity, irritation allergic response and other problem complications commensurate with a reasonable benefit / risk ratio.
  • treating comprises a treatment relieving, reducing or alleviating at least one symptom in a subject or effecting a delay of progression of a disease.
  • treatment can be the diminishment of one or several symptoms of a disorder or complete eradication of a disorder, such as cancer.
  • the term “treat” also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease.
  • prevent includes the prevention of at least one symptom associated with or caused by the state, disease or disorder being prevented.
  • pharmaceutically effective amount of a combination of therapeutic agents is an amount sufficient to provide an observable improvement over the baseline clinically observable signs and symptoms of the disorder treated with the combination.
  • subject or “patient” as used herein includes animals, which are capable of suffering from or afflicted with at least one neuroendocrine tumor or any disorder involving, directly or indirectly, a neuroendocrine tumor.
  • subjects include mammals, e.g., humans, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits rats and transgenic non- human animals.
  • the subject is a human, e.g., a human suffering from, at risk of suffering from, or potentially capable of suffering from a neuroendocrine tumor.
  • a "subject in need thereof” or “patient in need thereof” as hused herein includes a subject or patient suffering from or afflicted with the identified neuroendocrine tumor or any disorder involving, directly or indirectly, said neuroendocrine tumor.
  • the term about” or “approximately” shall have the meaning of within 10%, more preferably within 5%, of a given value or range.
  • WO2006/122806 and WO2008/103636 describe imidazoquinoline derivatives, which have been found to inhibit the activity of phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR).
  • PI3K phosphatidylinositol-3-kinase
  • mTOR mammalian target of rapamycin
  • R-i is naphthyl or phenyl wherein said phenyl is substituted by one or two substituents independently selected from the group consisting of Halogen; lower alkyl unsubstituted or substituted by halogen, cyano, imidazolyl or triazolyl; cycloalkyl; amino substituted by one or two substituents independently selected from the group consisting of lower alkyl, lower alkyl sulfonyl, lower alkoxy and lower alkoxy lower alkylamino; piperazinyl unsubstituted or substituted by one or two substituents independently selected from the group consisting of lower alkyl and lower alkyl sulfonyl; 2-oxo-pyrrolidinyl; lower alkoxy lower alkyl; imidazolyl; pyrazolyl; and triazolyl;
  • R 2 is O or S
  • R 3 is lower alkyl
  • R 4 is pyridyl unsubstituted or substituted by halogen, cyano, lower alkyl, lower alkoxy or piperazinyl unsubstituted or substituted by lower alkyl; pyrimidinyl unsubstituted or substituted by lower alkoxy; quinolinyl unsubstituted or substituted by halogen; or quinoxalinyl;
  • R 5 is hydrogen or halogen
  • n 0 or 1 ;
  • R 6 is oxido
  • the prefix “lower” denotes a radical having up to and including a maximum of 7, especially up to and including a maximum of 4 carbon atoms, the radicals in question being either linear or branched with single or multiple branching.
  • alkyl has up to a maximum of 12 carbon atoms and is especially lower alkyl.
  • “Lower alkyl” is preferably alkyl with from and including 1 up to and including 7, preferably from and including 1 to and including 4, and is linear or branched; preferably, lower alkyl is butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or preferably methyl.
  • Cycloalkyl is preferably cycloalkyl with from and including 3 up to and including 6 carbon atoms in the ring; cycloalkyl is preferably cyclopropyl, cyclobutyl , cyclopently or cyclohexyl.
  • Alkyl which is substituted by halogen is preferably perfluoro alkyl such as
  • Halogen is especially fluorine, chlorine, bromine, or iodine, especially fluorine, chlorine, or bromine.
  • the compound of formula (I) may be present in the form of the free base or a
  • Suitable salts of the compounds of formula (I) include those formed, for example, as acid addition salts, preferably with organic or inorganic acids.
  • Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
  • Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, malonic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid,
  • cyclohexanecarboxylic acid adamantanecarboxylic acid, benzoic acid, salicylic acid, 4- aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1 ,2-disulfonic acid, benzenesulfonic acid, 4-toluenesulfonic acid, 2-naphthalenesulfonic acid, 1 ,5-naphthalene-disulfonic acid, 2- or 3-methylbenzenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N- cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such
  • Preferred compounds of formula (I) for use in the present invention are 2-methyl-2-[4-(3- methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile ("COMPOUND A”) or its monotosylate salt and 8-(6-methoxy-pyridin-3-yl)-3-methyl-1 -(4- piperazin-1 -yl-3-trifluoromethyl-phenyl)-1 ,3-dihydro-imidazo[4,5-c]quinolin-2-one (“COMPOUND B").
  • the compound of formula (I) is 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin- 3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile ("COMPOUND A”) or its monotosylate salt.
  • the compound of formula (I) or a pharmaceutically acceptable salt thereof, alone or in combination with other therapeutic agents, is useful for the treatment of a neuroendocrine tumor, particularly pancreatic neuroendocrine tumor, which is resistant or refractory to treatment with at least one mTOR inhibitor.
  • Neuroendocrine tumors suitable for treatment in accordance with the present invention are those resistant or refractory to treatment at least one mTOR inhibitor (i.e, an mTOR inhibitor in the absence of a phosphatidylinositol-3-kinase (PI3K) inhibitor).
  • mTOR inhibitor i.e, an mTOR inhibitor in the absence of a phosphatidylinositol-3-kinase (PI3K) inhibitor.
  • Neuroendocrine tumors arise from neuroendocrine cell.
  • PI3K phosphatidylinositol-3-kinase
  • neuroendocrine tumors suitable for treatment in accordance with the present invention include, but not limited to, carcinoid tumors, pancreatic neuroendocrine tumors, pheochromocytoma, Merkel cell cancer, MEN1 , and MEN2.
  • the mTOR inhibitor i.e, an mTOR inhibitor in the absence of a phosphatidylinos
  • neuroendocrine tumor is a carcinoid tumor or a pancreatic neuroendocrine tumor. Most preferably, the neuroendocrine tumor is a pancreatic neuroendocrine tumor.
  • Carcinoid tumors belong to the family of neuroendocrine tumors which derive from the neuroendocrine cell system. In the intestinal tract, these tumors develop deep in the mucosa, growing slowly and extending into the underlying submucosa and mucosal surface. This results in the formation of small firm nodules, which bulge into the intestinal lumen.
  • Carcinoid tumors have historically been classified, according to their point of origin in embryonic development, as arising from the foregut (e.g., bronchial, pulmonary or gastric carcinoid), midgut (e.g., small intestine or appendiceal carcinoid), or hindgut (e.g., rectal carcinoid), see e.g. Kulke M., Cancer Treatment Reviews 2003;29:363-370.
  • foregut e.g., bronchial, pulmonary or gastric carcinoid
  • midgut e.g., small intestine or appendiceal carcinoid
  • hindgut e.g., rectal carcinoid
  • Primary foregut tumors e.g., bronchial, pulmonary or gastric carcinoids, e.g. including primary foregut tumors confined to the thymus, lung, stomach, and duodenum; e.g. carcinoid tumors of the Gl tract, e.g. located in the colon, stomach or small intestine, e.g. small-intestinal carcinoids,
  • Midgut carcinoids e.g., small intestine or appendiceal carcinoids, e.g. located in the distal ileum, cecum, and proximal colon, or
  • Hindgut tumors e.g, distal colon and rectal carcinoids. Data suggest that the incidence of pulmonary and gastric carcinoid has increased in the past two decades.
  • carcinoids can be divided into typical (TC) and atypical (AC) carcinoids.
  • Carcinoids can be placed in a spectrum of neuroendocrine tumors, ranging from low-grade malignant TC to intermediate AC to high-grade large-cell
  • Carcinoid lung tumors as indicated herein include neuroendocrine carcinoma, Kulchitsky cell carcinoma (KCC) (Kulchitsky cells, argentaffin cells), bronchial carcinoid tumors, bronchial adenomas, e.g.
  • KCC Kulchitsky cell carcinoma
  • argentaffin cells Kulchitsky cells, argentaffin cells
  • bronchial carcinoid tumors bronchial adenomas, e.g.
  • bronchial adenomas such as a small cell carcinoma and large cell neuroendocrine tumors, typical carcinoids or atypical carcinoids associated with large bronchopulmonary carcinoid tumors or small-cell carcinomas, pulmonary carcinoids, neuroendocrine lung tumors, large-cell neuroendocrine carcinoma of the lung, (primary) pulmonary neoplasms, bronchopulmonary carcinoid tumors, lung neoplasms, lung cancers, pulmonary cancers, intrabronchial mass.
  • bronchial adenomas such as a small cell carcinoma and large cell neuroendocrine tumors, typical carcinoids or atypical carcinoids associated with large bronchopulmonary carcinoid tumors or small-cell carcinomas, pulmonary carcinoids, neuroendocrine lung tumors, large-cell neuroendocrine carcinoma of the lung, (primary) pulmonary neoplasms, bronchopulmonary carcinoid tumors, lung neoplasms, lung
  • Typical carcinoid tumors of the lung represent the most well differentiated and least biologically aggressive type of pulmonary neuroendocrine tumor.
  • Carcinoid syndrome has been reported in association with very large bronchopulmonary carcinoid tumors or in the presence of metastatic disease. It is noted much less frequently in association with carcinoids of pulmonary origin than those originating within the gastrointestinal tract.
  • Bronchial carcinoid tumors belong to a group of neuroendocrine tumors, which cover a range of tumors ranging from bronchial carcinoid at one of the spectrum, with a small cell carcinoma, or possibly large cell neuroendocrine tumors at the other end. They demonstrate a wide range of clinical and biologic behaviors, including the potential to synthesize and secrete peptide hormones and neuroamines, particularly adrenocorticotropic hormone (ACTH), serotonin, somatostatin, and bradykinin.
  • Bronchial carcinoid tumors may originate from the neurosecretory cells of bronchial mucosa.
  • Bronchial carcinoids are now classed as low-grade malignant neoplasms because of their potential to cause local invasion, their tendency for local recurrence, and their occasional metastases to extrathoracic sites.
  • Bronchial carcinoid tumors may arise from Kulchitsky cells (argentaffin cells) within the bronchial mucosa. The predominant distribution of cells are believed to occur at the bifurcation of the lobar bronchi. These cells are neurosecretory cells, which belong to the amine precursor uptake and decarboxylation (APUD) system. They have the capacity to synthesize serotonin (5- hydroxytryptamine), 5-hydroxytryptophan, ACTH, norepinephrine, bombesin, calcitonin, antidiuretic hormone (ADH), and bradykinin.
  • APUD amine precursor uptake and decarboxylation
  • Carcinoid tumors of the Gl tract may display an aggressive biology similar to that of adenocarcinomas, particularly when they are located in the colon, stomach, and small intestine, see e.g. Modlin IM et al, Gastroenterology 2005; 128:1717-1751.
  • Modlin IM et al Gastroenterology 2005; 128:1717-1751.
  • small-intestinal carcinoids which are the most frequent cause of carcinoid syndrome due to metastatic disease in the liver, the incidence of metastasis increases proportionally with the size of the primary tumor
  • Carcinoid syndrome is caused by hypersecretion of numerous hormone products by the tumor cells, including kinins, prostaglandins, substance P, gastrin, corticotrophin and chromogranin A (see e.g. Davis et al, Gynecology & Obstetrics 1973;137:637-644).
  • Various endocrine or neuroendocrine syndromes can be initial clinical manifestations of either typical or atypical pulmonary carcinoid tumors.
  • Carcinoid syndrome hypercortisolism and Cushing syndrome, inappropriate secretion of ADH, increased pigmentation secondary to excess MSH, and ectopic insulin production resulting in hypoglycemia are some of the endocrinopathies that can be produced by a pulmonary carcinoid tumor in a patient who is otherwise asymptomatic.
  • Pancreatic neuroendocrine tumors (islet cell tumors), which were formerly classified as
  • APUDomas tumors of the amine precursor uptake and decarboxylation system
  • pancreatic NETs can arise either in the pancreas (insulinomas, glucagonomas, nonfunctioning pancreatic NETs, pancreatic NETs causing hypercalcemia) or at both pancreatic and extrapancreatic sites (gastrinomas, VIPomas, somatostatinomas, GRFomas).
  • the hormones secreted by pancreatic NETs depend upon the cell of origin and are physiologically involved in a network of autocrine, paracrine, endocrine and neurotransmitter communication.
  • pancreatic NETs While hormone secretion is not observed in all cases of pancreatic NET, the apparently "nonfunctioning" (i.e., non-secreting) pancreatic NETs tend to be more aggressive and present with symptoms of tumor bulk (see e.g. Barakat et al, Endocrine-related cancer 2004;1 1 :1-18 and Tomassetti et al, Ann Oncol
  • Pancreatic neuroendocrine tumors as indicated herein e.g. include islet cell tumors, APUDomas, insulinomas, glucagonomas, nonfunctioning pancreatic NETs, pancreatic NETs associated with hypercalcemia, gastrinomas, VIPomas, somatostatinomas, GRFomas.
  • neuroendocrine tumors include: pheochromocytoma, Merkel cell cancer, Multiple Endocrine Neoplasia Type 1 (MEN1 ), Multiple Endocrine Neoplasia Type 2 (MEN2).
  • MEN1 Multiple Endocrine Neoplasia Type 1
  • MEN2 Multiple Endocrine Neoplasia Type 2
  • a tumor a tumor disease, a carcinoma or a cancer
  • metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis is.
  • the compounds of the present invention are particularly useful for the treatment of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • a tumor "resistant or refractory to treatment with at least one mTOR inhibitor” as used herein refers to a tumor that either fails to respond favorably to treatment with at least one compound which directly inhibits the mammalian target of rapaymycin (mTOR) kinase, or alternatively, recurs or relapses after responding favorably to treatment with at least one compound which directly inhibits the mammalian target of rapaymycin (mTOR) kinase.
  • Said compound which directly inhibits the mammalian target of rapaymycin (mTOR) kinase in the absence of a PI3K inhibitor.
  • absent PI3K inhibitors may include but are not limited to: 2-methyl-2- [4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile; 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1 -yl-3-trifluoromethyl-phenyl)-1 ,3-dihydro- imidazo[4,5-c]quinolin-2-one, 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2- ylamine (described in WO 2007/084786); 4-[2-(1 H-lndazol-4-yl)-6-[[4-(methylsulfony
  • the tumor may be resistant or refractory at the beginning of treatment or it may become resistant or refractory during treatment.
  • the tumor fails to respond, or alternatively, recurs or relapses after responding favorably to treatment either while on treatment with at least one mTOR inhibitor or within 3 months of treatment discontinuation.
  • mTOR inhibitor examples include, but is not limited to, compounds, proteins or antibodies which target/inhibit members of the mTOR kinase family, e.g., RAD, rapamycin (sirolimus) and derivatives/analogs thereof such as everolimus or RAD001.
  • Sirolimus is also known by the name RAPAMUNE ® , and everolimus (or RAD001 ) by the name AFINITOR ® .
  • mTOR inhibitors include, but not limited to, I. Rapamycin which is an immunosuppressive lactam macrolide that is produced by
  • Rapamycin derivatives such as:
  • rapamycin e.g. a 40-O-substituted rapamycin e.g. as described in US 5,258,389, WO 94/09010, WO 92/05179, US 5, 1 18,677, US 5, 1 18,678, US 5, 100,883, US 5,151 ,413, US 5,120,842, WO 93/1 1 130, WO 94/02136, WO 94/02485 and WO 95/14023 all of which are incorporated herein by reference;
  • rapamycin e.g. as disclosed in WO 94/02136, WO 95/16691 and WO 96/41807, the contents of which are incorporated herein by reference;
  • a 32-hydrogenated rapamycin e.g. as described in WO 96/41807 and US 5 256 790, incorporated herein by reference.
  • Preferred rapamycin derivatives are compounds of formula (II)
  • Ri is CH 3 or C 3-6 alkynyl
  • R 2 is -CH 2 -CH 2 -OH, e.g. a physiologically hydrolysable ether thereof.
  • Preferred compounds are 32- deoxorapamycin, 16-pent-2-ynyloxy-32-deoxorapamycin, 16-pent-2-ynyloxy-32(S)-dihydro- rapamycin, 16-pent-2-ynyloxy-32(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin and, more preferably, 40-0-(2-hydroxyethyl)-rapamycin, disclosed as Example 8 in WO 94/09010.
  • rapamycin derivatives of formula (II) are 40-O-(2-hydroxyethyl)-rapamycin, 40-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin (also called CCI779), 40-epi- (tetrazolyl)-rapamycin (also called ABT578), 32-deoxorapamycin, 16-pent-2-ynyloxy-32(S)- dihydro rapamycin, or TAFA-93.
  • Rapamycin derivatives also include so-called rapalogs, e.g. as disclosed in WO 98/02441 and WO 01/14387, e.g. AP23573, AP23464, or AP23841.
  • AZD08055 and OSI127 which are compounds that inhibit the kinase activity of mTOR by directly binding to the ATP-binding cleft of the enzyme.
  • the mTOR inhibitor is everolimus (RAD001 ).
  • the neuroendocrine tumor treated in accordance with the present invention is a carcinoid tumor or pancreatic NET (pNET) resistant or refractory to treatment with everolimus (RAD001 ) or a pharmaceutically acceptable salt thereof as single agent.
  • pNET pancreatic NET
  • the neuroendocrine tumor treated in accordance with the present invention is a pancreatic NET (pNET) resistant or refractory to treatment with everolimus (RAD001 ) or a pharmaceutically acceptable salt thereof as single agent.
  • pNET pancreatic NET
  • a patient undergoing initial treatment can be carefully monitored for signs of resistance, non- responsiveness, progressing or recurring tumors. This can be accomplished by monitoring the patient's tumor's response to the initial treatment with the mTOR inhibitor.
  • the response, lack of response, or relapse of the tumor compared to the initial tumor can be determined by any suitable method practiced in the art. For example, this can be accomplished by the assessment of tumor size and number. An increase in tumor size or, alternatively, tumor number, indicates that the tumor is not responding to the treatment with the mTOR inhibitor or that a relapse has occurred.
  • a patient having a neuroendocrine tumor resistant or refractory to the mTOR inhibitor may be treated by administration of a compound of formula (I) or a pharmaceutically acceptable salt thereof to said patient in need thereof.
  • the present invention further provides in several aspects:
  • a method for inhibiting growth of a neuroendocrine tumor comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • a method for inducing neuroendocrine tumor regression comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • a method for preventing metastatic spread of neuroendocrine tumors or for preventing or inhibiting growth of micrometastasis comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in the treatment of a neuroendocrine tumor, particularly a carcinoid tumor or a pancreatic
  • neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in the treatment of a pancreatic neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in inhibiting growth of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in inducing regression of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in preventing metastatic spread of neuroendocrine tumors or for preventing or inhibiting growth of micrometastasis, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for treating a neuroendocrine tumor, particularly a carcinoid tumor or a pancreatic neuroendocrine tumor, resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for treating a pancreatic neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for inhibiting growth of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for inducing regression of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to the use of compound of formula (I) or a pharmaceutically acceptable salt thereof for preventing metastatic spread of neuroendocrine tumors or for preventing or inhibiting growth of micrometastasis, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a neuroendocrine tumor, particularly a carcinoid tumor or a pancreatic neuroendocrine tumor, resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a pancreatic neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in inhibiting growth of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in inducing regression of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention further relates to a compound of formula (I) or a pharmaceutically acceptable salt for use in preventing metastatic spread of neuroendocrine tumors or for preventing or inhibiting growth of micrometastasis, wherein said neuroendocrine tumor is resistant or refractory to treatment with at least one mTOR inhibitor.
  • the compound of formula (I) may also be used or administered in combination with at least one additional therapeutic compounds for the treatment of a neuroendocrine tumor, particularly a carcinoid tumor or a pancreatic
  • the compound of formula (I) may be used or administered in combination with at least one additional therapeutic compounds for any of the methods and uses disclosed above.
  • additional therapeutic agents for use in said combination include but are not limited to somatostatin analogs, including but not limited to octreotide, lanreotide, and SOM230; proton pump inhibitors; diazoxide; pancrealipase (lipase, protease, and amylase); anti-diarrheals, including but not limited to Imodium or Lomotil, opiates, etc.; antiemetics, including but not Imited to aprepitant (Emend®) or ondansetron (Zofran®); bisphosphonates; erithropoietin replacement; cortocosteroids administered by topical, inhalation, eye drops or local injection only; anticoagulants (excluding warfarin/ coumarin derivatives
  • somatostatin analogues which may be used in the present invention include, but are not limited to, compounds which target, treat or inhibit the somatostatin receptor such as octreotide, lanreotide, and SOM230.
  • proton pump inhibitors which may be used in the present invention include, but are not limited to, omeprazole (Prilosec®), lansoprazole (Prevacid®), dexlansoprazole (Dexilant®), and pantoprazole (Protonix®).
  • bisphosphonates which may be used in the present invention include, but are not limited to, etridonic, clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid.
  • Etridonic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark DIDRONEL.
  • Clodronic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONEFOS.
  • titaniumudronic acid can be administered, e.g., in the form as it is marketed, e.g. under the trademark SKELID.
  • Pamidronic acid can be administered, e.g. in the form as it is marketed, e.g. under the trademark AREDIATM.
  • “Alendronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark FOSAMAX.
  • “Ibandronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark BONDRANAT.
  • “Risedronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the trademark ACTON EL.
  • “Zoledronic acid” can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZOMETA.
  • Radiation may include approaches such as ionizing radiation.
  • ionizing radiation means ionizing radiation that occurs as either electromagnetic rays (such as X-rays and gamma rays) or particles (such as alpha and beta particles). Ionizing radiation is provided in, but not limited to, radiation therapy and is known in the art. See Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of Oncology, Devita et al., Eds., 4 th Edition, Vol. 1 , pp. 248-275 (1993).
  • the compound of formula (I) is administered in combination with a somatostatin analogue, particularly octreotide, lanreotide, and SOM230.
  • the present invention relates to a method for treating a
  • neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with at least one additional therapeutic agent.
  • the present invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with at least one additional therapeutic compound for the manufacture of a medicament for use the treatment of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof which is administered in combination with a therapeutically effective amount of at least one additional therapeutic agent for use in the treatment of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor, wherein the at least one additional therapeutic agent selected from the group consisting of somatostatin analogs, proton pump inhibitors, diazoxide, pancrealipase (lipase, protease, and amylase), anti-diarrheals, antiemetics, bisphosphonates; erithropoietin replacement; cortocosteroids administered by topical, inhalation, eye drops or local injection only; anticoagulants (excluding warfarin/ coumarin derivatives or anti-aggregation agents), and radiotherapy, or a combination thereof.
  • the at least one additional therapeutic agent selected from the group consisting of somatostatin analogs, proton pump inhibitors, diazoxide, pancrealipase (lipas
  • ком ⁇ онент there is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and a combination partner may be administered independently, at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g.
  • a compound of formula (I) can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed
  • a combination partner may be administered in combination therapy as appropriate, e.g. according to a method as conventional, e.g. analogously to administration indications given for a specified drug for single treatment.
  • Said combination partner may be administered by any conventional route, for example enterally, e.g. including nasal, buccal, rectal, oral, administration; parenterally, e.g. including intravenous, intraarterial, intramuscular, intracardiac, subcutanous, intraosseous infusion, transdermal (diffusion through the intact skin), transmucosal (diffusion through a mucous membrane), inhalational administration; topically; e.g. including epicutaneous, intranasal, intratracheal administration; intraperitoneal (infusion or injection into the peritoneal cavity);
  • enterally e.g. including nasal, buccal, rectal, oral, administration
  • parenterally e.g. including intravenous, intraarterial, intramuscular, intracardiac, subcutanous, intraosseous infusion, transdermal (diffusion through the intact skin), transmucosal (diffusion through a mucous membrane), inhalational administration
  • topically e.
  • epidural peripheral
  • intrathecal injection or infusion into the cerebrospinal fluid
  • intravitreal administration via the eye
  • medical devices for example, in form of coated or uncoated tablets, capsules, (injectable) solutions, infusion solutions, solid solutions, suspensions, dispersions, solid dispersions; e.g. in the form of ampoules, vials, in the form of creams, gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops, sprays, or in the form of suppositories.
  • the present invention relates to a combination comprising (a) a compound of formula (I) or a pharmaceutically acceptable salt thereof, and (b) at least one additional therapeutic agent, for use in the treatment of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention relates to a combination comprising (a) 2- methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl)-phenyl]- propionitrile (COMPOUND A) or a pharmaceutically acceptable salt thereof, and (b) at least one additional therapeutic agent, for use in the treatment of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the present invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for use in combination with at least one therapeutic agent for any use as indicated above.
  • a compound of formula (I) may a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically accepable salt thereof in association with at least one pharmaceutically acceptable excipient, e.g. appropriate carrier and/or diluent, e.g.
  • fillers including fillers, binders, disintegrants, flow conditioners, lubricants, sugars or sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers, for use in the treatment of a neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • the dosage of the active ingredient depends upon a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed.
  • a physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Optimal precision in achieving concentration of drug within the range that yields efficacy requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
  • the dose of a compound of the formula (I) or a pharmaceutically acceptable salt thereof to be administered to subject in need thereof, for example humans of approximately 70 kg body weight, is preferably from approximately 3 mg to approximately 5 g, more preferably from approximately 10 mg to approximately 1.5 g, most preferably from about 100 mg to about 1000 mg per person per day, divided preferably into 1 to 3 single doses which may, for example, be of the same size. Usually, children receive half of the adult dose.
  • the compounds of the invention may be administered by any conventional route, in particular parenterally, for example in the form of injectable solutions or suspensions, enterally, e.g. orally, for example in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form.
  • Topical administration is e.g. to the skin.
  • a further form of topical administration is to the eye.
  • Pharmaceutical compositions comprising a compound of the invention in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent.
  • compositions are comprising an amount effective in the treatment of one of the above-mentioned neuroendocrine tumors, of a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with at least one pharmaceutically acceptable carrier that is suitable for topical, enteral, for example oral or rectal, or parenteral administration and that may be inorganic or organic, solid or liquid.
  • pharmaceutical compositions used for oral administration especially tablets or gelatin capsules that comprise the active ingredient together with diluents, for example lactose, dextrose, manitol, and/or glycerol, and/or lubricants and/or polyethylene glycol.
  • Tablets may also comprise binders, for example magnesium aluminum silicate, starches, such as corn, wheat or rice starch, gela ⁇ tin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or adsorbents, dyes, flavorings and sweeteners. It is also possible to use the pharmacologically active compounds of the present invention in the form of parenterally administrable compositions or in the form of infusion solutions.
  • binders for example magnesium aluminum silicate, starches, such as corn, wheat or rice starch, gela ⁇ tin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone
  • disintegrators for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or efferv
  • the pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting compounds and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.
  • excipients for example preservatives, stabilizers, wetting compounds and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.
  • the present pharmaceutical compositions which may, if desired, comprise other pharmacologically active substances are prepared in a manner known per se, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising lyophilizing processes, and comprise approximately from 1 % to 99%, especially from approximately 1 % to approximately 20%, active ingredient(s).
  • the present invention provides:
  • a pharmaceutical package comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and instructions for administration for the treatment of a
  • a pharmaceutical package comprising a first drug substance which is a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent, beside instructions for combined administration;
  • a pharmaceutical package comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof beside instructions for combined administration with at least one additional therapeutic agent;
  • a pharmaceutical package comprising at least one second therapeutic agent beside
  • solvates, hydrates and polymorphs which are disclosed therein.
  • the compounds used as active ingredients in the combinations of the invention may be prepared and administered as described in the cited documents or in the product description, respectively. Also within the scope of this invention is the combination of more than two separate active ingredients as set forth above, i. e. a pharmaceutical combination within the scope of this invention could include three active ingredients or more. Further, both the first agent and the co-agent are not the identical ingredient.
  • the present invention relates to the use of the compound 2- methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl)-phenyl]- propionitrile ("COMPOUND A”) or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for use in the treatment of pancreatic neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • COMPONENT A 2- methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl)-phenyl]- propionitrile
  • the present invention relates to the use of the compound 2- methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl)-phenyl]- propionitrile ("COMPOUND A”) or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for use in the treatment of pancreatic neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • COMPONENT A 2- methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl)-phenyl]- propionitrile
  • the present invention relates to the use of the compound 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]- propionitrile ("COMPOUND A”) or a pharmaceutically acceptable salt thereof for use in the treatment of pancreatic neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • COMPONENT A 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]- propionitrile
  • the present invention relates to a compound 2-methyl-2-[4- (3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl)-phenyl]-propionitrile ("COMPOUND A”) or a pharmaceutically acceptable salt thereof for use in the treatment of pancreatic neuroendocrine tumor resistant or refractory to treatment with at least one mTOR inhibitor.
  • COMPONENT A 2-methyl-2-[4- (3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl)-phenyl]-propionitrile
  • Utility of the compounds of formula (I) in treating a neuroendocrine tumor, particularly pancreatic NET, resistant or refractory to treatment with at least one mTOR inhibitor as hereinabove specified may be demonstrated in vitro, in animal test methods as well as in clinic studies.
  • Utility of the compounds of formula (I) in accordance with the present invention may be demonstrated in accordance with the methods hereinafter described:
  • Example 1 Clinical Trial A clinical study using Compound A or its monotosylate salt in an amount of 400 mg twice daily (b.i.d.) Compound A in monotherapy for treatment of patients with advanced pancreatic neuroendocrin tumors (pNET) after failure of mTOR inhibitor therapy is investigated.
  • a prospective, global, multi-center, two stage study of Compound A or the monotosylate salt of Compound A is conducted in adult patients who are diagnosed with a advanced
  • pancreatic neuroendocrine tumor which is refractory to treatment with at least one mTOR inhibitor.
  • refractory is defined as progression while on treatment or within 3 months of treatment discontinuation.
  • SSA somatostatin analogue
  • Hemoglobin > 9 g/dL in case of blood transfusions, hemoglobin must be stable for at least 2 weeks before first dose of study medication
  • FPG Fasting plasma glucose
  • patients having received previous treatment with any PI3K inhibitor or AKT inhibitor for treatment of pNET patients having discontinued prior mTOR inhibitor therapy due to toxicity, and patients having poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma. Additional criteria for exclusion include:
  • Patient is being treated at start of study treatment with any of the following drugs: (a) Drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A4 including herbal medications (list of prohibited CYP3A4 inhibitors and inducers to be provided in final protocol). The patient must have discontinued strong inducers and/or strong inhibitors two weeks before the treatment is initiated. Switching to a different medication prior to starting study treatment is allowed. Or (b) Drugs with a known risk to induce Torsades de Pointes, Or (c) Warfarin and coumarin analogues
  • Patient has any of the following cardiac abnormalities: symptomatic congestive heart failure, myocardial infarction ⁇ 6 months prior to enrollment; unstable angina pectoris; serious uncontrolled cardiac arrhythmia; symptomatic pericarditis; history of documented congestive heart failure (New York Heart Association functional classification lll-IV), documented cardiomyopathy; abnormal Left Ventricular Ejection Fraction (LVEF) as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO); QTcF > 480 msec on the screening ECG (using the QTcF formula); or currently receiving treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug.
  • Gl gastrointestinal
  • Gl gastrointestinal
  • Patient is receiving chronic high dose treatment with corticosteroids (e.g. total daily dose of prednisone at 1 mg per kg of body weight, or approximately 60 milligrams a day or equivalent dose of other corticosteroid) or another immunosuppressive agent that would cause the patient to be immunocompromised.
  • corticosteroids e.g. total daily dose of prednisone at 1 mg per kg of body weight, or approximately 60 milligrams a day or equivalent dose of other corticosteroid
  • another immunosuppressive agent that would cause the patient to be immunocompromised.
  • Patient is immunocompromised, including known seropositivity for HIV.
  • Patient has a history of non-compliance to medical regimen or is considered potentially unreliable or is unable to grant consent.
  • Patient is a pregnant or nursing (lactating) woman, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mlU/mL). Patients with elevated hCG at baseline that is judged to be related to the tumor are eligible if hCG levels do not show the expected doubling when repeated 5-7 days later, or pregnancy has been ruled out by vaginal ultrasound.
  • IUD intrauterine device
  • IUS intrauterine system
  • OC Occlusive cap
  • spermicidal foam/gel/film/cream/vaginal suppository a Placement of an intrauterine device (IUD) or intrauterine system (IUS)
  • OC Occlusive cap
  • Hormonal contraception methods e.g. oral, injected, implanted are not allowed.
  • Patients are orally administered 400 mg B.I.D. Compound A in the form of its free base or its monotosylate salt. For each patient, a maximum of 2 dose reductions are allowed. Dose per administration may be reduced to 300 mg B.I.D. Compound A and then to 200 mg B.I.D. Compound A. Doses below 200 mg per administration (400 mg total daily dose) are not permitted. For patients who experience any intolerable toxicity, the study treatment is withheld until the toxicity resolves to Grade 1 or better. Patients are permitted to receive additional Best Supportive Care treatment during the study treatment.
  • Best Supportive Care includes all care provided to patients deemed necessary by the treating physician, such as, the use of somatostatin analogs; proton pump inhibitor for gastrinoma; diazoxide, short course of steroids or feeding tube for insulinoma; Pancrealipase (lipase, protease, and amylase) for patients with pancreatic exocrine insufficiency; and nonspecific anti-diarrheals, such as, imodium or lomotil (containing loperamide), opiates, etc.
  • Best Supportive care excludes the use of anti-tumor therapies such as interferon, targeted/biological agent (e.g.
  • This concomitant therapy may further include: (a) antiemetics once patient experiences nausea or vomiting and at discretion of investigator, bisphosphonates if patient has been on stable doses for at least 2 weeks prior to screening procedures, erithropoietin replacemet if initiated greater than 2 weeks prior to treatment, cortocosteroids as topical, inhaled, eye drops or local injection only, anticoagulants other than warfarin/ coumarin derivatives or anti-aggregation agents, or radiotherapy.
  • PFS Progression-Free Survival
  • a complete treatment cycle is defined as a period of 28 days (+ 4 days). Following study inclusion and initiation of study treatment, the patient is encouraged to visit the site on Day 1 , 8, 15, and 22 for the first cycle and every 14 days thereafter during the treatment phase. Patients will have their first dose of study drug at Visit 2 (Day 1 , Cycle 1 ).
  • Patients receiving placebo may be permitted to cross-over to Compound A treatment if one of the following criteria are met: (a) In Stage 1 , the PFS rate at 16 weeks is > 75%, or (b) If criterion (a) is not fulfilled, the estimate hazard ratio (HR) based on an interim analysis of the second stage after approximately 30 events are observed), is ⁇ 0.6. Before crossing over, patients are re-evaluated to ensure eligibility for the trial.
  • Patients are assessed for efficacy via radiographic tumor assessments every 8 weeks (+1 week) fro the date of initiation of study treatment in Stage 1 and from the randomization date in Stage 2 until documented disease progression or start of new anti-neoplastic therapy, whichever occurs first. Additional tumor assessments may be performed if there is symptomatic evidence suggesting the possibility of disease progression based on clinical symptoms or physical examination.
  • the primary endpoint is the PFS rate as per modified RECIST v. 1 .1 criteria.
  • Overall tumor response and disease progression are assessed locally according to modified RECIST v. 1 .1 criteria.
  • the following criteria is applied when determining tumor status:
  • Safety assessments and PK assessments are routinely performed. Safety assessments consist of monitoring, by investigators, and recording of all adverse events (non-serious and serous) and concomitant medications, and the regular monitoring of laboratory tests, physical examinations, weight, vital signs, cardiac health and WHO Performance Status (PS).
  • PS WHO Performance Status
  • hemoglobin hematocrit, platelet counts, total red blood cells, total white blood cells and a WBC differential including neutrophils, lymphocytes, monocytes, eosinophils and basophils), clinical chemistry, cooagultion, C-peptide and HbA1 c analysis, fasting plasma glucose, urinalysis, serum lipid profile and optionally thyroid activity.
  • End of post-treatment electronic case report/ record form is completed once a patient has discontinued study treatment, completed safety follow-up and can no longer perform efficacy assessment.
  • Safety and efficacy of the use of the monotosylate salt of Compound A may be assessed and/or determined through use of interim study data.
  • Compound A monotosylate salt a) 2 patients receiving ongoing treatment with 400 mg BID Compound A monotosylate salt for 50 day, (b) 1 patient receiving ongoing treatment with 400 mg BID Compound A monotosylate salt for 8 days, and (c) 2 patients receiving ongoing treatment with 400 mg BID Compound A monotosylate salt for 3 days. Additionally, 1 patient is receiving ongoing treatment at the dosage of 200 mg BID Compound A monotosylate salt for 15 days after receiving treatment with 400 mg BID Compound A monotosylate salt for 3 days and then with 300 mg BID Compound A monotosylate salt for 3 days.
  • Compound A or its monotosylate salt in an amount of 300 mg twice daily (b.i.d.) Compound A in monotherapy for treatment of patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy is a clinical study using Compound A or its monotosylate salt in an amount of 300 mg twice daily (b.i.d.) Compound A in monotherapy for treatment of patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy is
  • a prospective, global, multi-center, two stage study of Compound A or the monotosylate salt of Compound A is conducted in adult patients who are diagnosed with a advanced
  • pancreatic neuroendocrine tumor which is refractory to treatment with at least one mTOR inhibitor.
  • refractory is defined as progression while on treatment or within 3 months of treatment discontinuation.
  • Patient must have advanced (unresectable or metastatic), histologically confirmed low or intermediate grade pancreatic pNET according to the World Health Organization (WHO) 2010 classification (grade 1 or 2) and show radiological evidence of disease progression since last treatment.
  • WHO World Health Organization
  • Patients' disease is refractory to treatment with mTOR inhibitor. Patients must not have taken another antineoplastic treatment between mTOR inhibitor and Compound A or its monotosylate salt. Refractory disease is defined as progression while on mTOR inhibitor treatment or within 3 months of treatment discontinuation. An mTOR inhibitor treatment must be the last systemic treatment received prior to study entry with the last dose administered within 4 weeks of study treatment start.
  • SSA somatostatin analogue
  • Hemoglobin > 9 g/dL in case of blood transfusions, hemoglobin must be stable for at least 2 weeks before first dose of study medication
  • ALT and AST ⁇ 3 x ULN (or ⁇ 5x ULN in patients with liver metastases)
  • FPG Fasting plasma glucose
  • patients having received previous treatment with any PI3K inhibitor or AKT inhibitor for treatment of pNET patients having discontinued prior mTOR inhibitor therapy due to toxicity, and patients having poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma. Additional criteria for exclusion include:
  • Patient has been treated with hepatic artery embolization, or cryoablation/ radiofrequency ablation of hepatic metastasis within 2 months of study treatment start.
  • Patient is being treated at start of study treatment with any of the following drugs: (a) Drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A4 including herbal medications (list of prohibited CYP3A4 inhibitors and inducers to be provided in final protocol). The patient must have discontinued strong inducers and/or strong inhibitors two weeks before the treatment is initiated. Switching to a different medication prior to starting study treatment is allowed. Or (b) Drugs with a known risk to induce Torsades de Pointes, Or (c) Warfarin and coumarin analogues
  • Patient has any of the following cardiac abnormalities: symptomatic congestive heart failure, myocardial infarction ⁇ 6 months prior to enrollment; unstable angina pectoris; serious uncontrolled cardiac arrhythmia; symptomatic pericarditis; history of documented congestive heart failure (New York Heart Association functional classification lll-IV), documented cardiomyopathy; abnormal Left Ventricular Ejection Fraction (LVEF) ⁇ 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO); QTcF > 480 msec on the screening ECG (using the QTcF formula); or currently receiving treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug.
  • LVEF Left Ventricular Ejection Fraction
  • MUGA Multiple Gated acquisition
  • ECHO echocardiogram
  • Gl gastrointestinal
  • Gl disease may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  • Patient is receiving chronic high dose treatment with corticosteroids (e.g. total daily dose of prednisone at 1 mg per kg of body weight, or approximately 60 milligrams a day or equivalent dose of other corticosteroid) or another immunosuppressive agent that would cause the patient to be immunocompromised.
  • corticosteroids e.g. total daily dose of prednisone at 1 mg per kg of body weight, or approximately 60 milligrams a day or equivalent dose of other corticosteroid
  • another immunosuppressive agent that would cause the patient to be immunocompromised.
  • Patient is immunocompromised, including known seropositivity for HIV.
  • Patient has a history of non-compliance to medical regimen or is considered potentially unreliable or is unable to grant consent.
  • Patient is a pregnant or nursing (lactating) woman, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mlU/mL). Patients with elevated hCG at baseline that is judged to be related to the tumor are eligible if hCG levels do not show the expected doubling when repeated 5-7 days later, or pregnancy has been ruled out by vaginal ultrasound.
  • IUD intrauterine device
  • IUS intrauterine system
  • OC Occlusive cap
  • spermicidal foam/gel/film/cream/vaginal suppository a. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
  • OC Occlusive cap
  • Hormonal contraception methods e.g. oral, injected, implanted are not allowed.
  • Patients are orally administered 300 mg B.I.D. Compound A in the form of its free base or its monotosylate salt. For each patient, a maximum of 2 dose reductions are allowed. Dose per administration may be reduced to 200 mg B.I.D. Compound A and then to 100 mg B.I.D. Compound A. Doses below 100 mg B.I.D. are not permitted. For patients who experience any intolerable toxicity, the study treatment is withheld until the toxicity resolves to Grade 1 or better.
  • Best Supportive Care includes all care provided to patients deemed necessary by the treating physician, such as, the use of somatostatin analogs; proton pump inhibitor for gastrinoma; diazoxide, short course of steroids or feeding tube for insulinoma; Pancrealipase (lipase, protease, and amylase) for patients with pancreatic exocrine insufficiency; and non- specific anti-diarrheals, such as, imodium or lomotil (containing loperamide), opiates, etc. Best Supportive care excludes the use of anti-tumor therapies such as interferon, targeted/biological agent (e.g.
  • This concomitant therapy may further include: (a) antiemetics once patient experiences nausea or vomiting and at discretion of investigator, bisphosphonates if patient has been on stable doses for at least 2 weeks prior to screening procedures, erithropoietin replacement if initiated greater than 2 weeks prior to treatment, cortocosteroids as topical, inhaled, eye drops or local injection only, anticoagulants other than warfarin/ coumarin derivatives or anti-aggregation agents, or radiotherapy.
  • PFS Progression-Free Survival
  • the primary endpoint is the PFS rate at 16 weeks as per modified RECIST v. 1 .1 criteria.
  • the PFS rate at 16 weeks is defines as the number of progression free patients divided by the total number of patients in the full analysis set.
  • the posterior probability is derived from the Bayesian posterior distribution of the PFS rate.
  • Randomization will be stratified by (a) current somatostatin analogue therapy (yes/no) and (b) elevated CgA > 2xULN and/or NSE > ULN. Prior to randomization, potential patients are screened upon registration in the IRT system for a period of 28 days to assess eligibility. Screening radiological tumor assessments are used as baseline if completed within 4 weeks prior to randomization (for second stage), with the exception of bone scans which may be obtained within 6 weeks of randomization.
  • Patients are orally administered 300 mg B.I.D.
  • Compound A in the form of its free base or its monotosylate salt. It may be permitted to allow a maximum of 2 dose reductions. Dose per administration may be reduced to 200 mg B.I.D. Compound A and then to 100 mg B.I.D. Compound A. Doses below 100 mg B.I.D. are not permitted.
  • Patients receiving placebo may be permitted to cross-over to Compound A treatment if one of the following criteria are met: (a) In Stage 1 , the PFS rate at 16 weeks is > 75%, or (b) If criterion (a) is not fulfilled, the estimate hazard ratio (HR) based on an interim analysis of the second stage after approximately 30 events are observed), is ⁇ 0.6Before crossing over, patients are re-evaluated to ensure eligibility for the trial.
  • Patients are assessed for efficacy via radiographic tumor assessments every 8 weeks (+1 week) from the date of initiation of study treatment in Stage 1 and from the randomization date in Stage 2 until documented disease progression, discontinuation according to criteria set forth below, or start of new anti-neoplastic therapy, whichever occurs first. Additional tumor assessments may be performed if there is symptomatic evidence suggesting the possibility of disease progression based on clinical symptoms or physical examination.
  • the primary endpoint is the PFS rate as per modified RECIST v. 1.1 criteria. Overall tumor response and disease progression are assessed locally according to modified RECIST v. 1.1 criteria. In addition to the RECIST v. 1 .1 criteria, the following criteria is applied when determining tumor status:
  • Safety assessments and PK assessments are routinely performed. Safety assessments consist of monitoring, by investigators, and recording of all adverse events (non-serious and serous) and concomitant medications, and the regular monitoring of laboratory tests, physical examinations, weight, vital signs, cardiac health and WHO Performance Status (PS).
  • PS WHO Performance Status
  • hemoglobin hematocrit, platelet counts, total red blood cells, total white blood cells and a WBC differential including neutrophils, lymphocytes, monocytes, eosinophils and basophils), clinical chemistry, cooagultion, C-peptide and HbA1 c analysis, fasting plasma glucose, urinalysis, serum lipid profile and optionally thyroid activity.
  • End of post-treatment electronic case report/ record form is completed once a patient has discontinued study treatment, completed safety follow-up and can no longer perform efficacy assessment.
  • Safety and efficacy of the use of the monotosylate salt of Compound A may be assessed and/or determined through use of interim study data.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement d'une tumeur neuroendocrine, en particulier d'une tumeur neuroendocrine pancréatique, ladite méthode comportant l'administration à un sujet qui en a besoin d'une quantité thérapeutiquement efficace d'un composé de la formule (I) ou d'un sel de qualité pharmaceutique de celui-ci, seul ou en combinaison avec au moins un agent thérapeutique, ladite tumeur neuroendocrine étant résistante ou réfractaire au traitement par au moins un inhibiteur de mTOR. L'invention concerne également des utilisations desdits composés pour la préparation d'un médicament à utiliser dans le traitement d'une tumeur neuroendocrine résistante ou réfractaire au traitement par au moins un inhibiteur de mTOR ; des utilisations dudit composé pour le traitement de ladite maladie ; des compositions pharmaceutiques associées et un emballage pharmaceutique pour celles-ci.
PCT/US2013/046690 2012-06-22 2013-06-20 Traitement d'une tumeur neuroendocrine WO2013192367A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12305728.3 2012-06-22
EP12305728 2012-06-22
US201361755715P 2013-01-23 2013-01-23
US61/755,715 2013-01-23

Publications (1)

Publication Number Publication Date
WO2013192367A1 true WO2013192367A1 (fr) 2013-12-27

Family

ID=49769361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/046690 WO2013192367A1 (fr) 2012-06-22 2013-06-20 Traitement d'une tumeur neuroendocrine

Country Status (2)

Country Link
TW (1) TW201402120A (fr)
WO (1) WO2013192367A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10457679B2 (en) 2015-09-17 2019-10-29 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN114209844A (zh) * 2022-01-27 2022-03-22 中以海德人工智能药物研发股份有限公司 一种用于治疗病毒性肝炎的药物组合物
WO2022106579A1 (fr) * 2020-11-20 2022-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composés pour traiter une maladie associée à la sénescence des macrophages

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
WO1992005179A1 (fr) 1990-09-19 1992-04-02 American Home Products Corporation Esters d'acide carboxylique de rapamycine
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
WO1993011130A1 (fr) 1991-12-03 1993-06-10 Smithkline Beecham Plc Derive de rapamycine et son utilisation medicinale
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
WO1994002485A1 (fr) 1992-07-17 1994-02-03 Smithkline Beecham Corporation Derives de rapamycine
WO1994002136A1 (fr) 1992-07-17 1994-02-03 Smithkline Beecham Corporation Derives de rapamycine
WO1994009010A1 (fr) 1992-10-09 1994-04-28 Sandoz Ltd. Derives o-alkyles de la rapamycine et leur utilisation, en particulier comme immunosuppresseurs
WO1995014023A1 (fr) 1993-11-19 1995-05-26 Abbott Laboratories Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
WO1995016691A1 (fr) 1993-12-17 1995-06-22 Sandoz Ltd. Derives de rapamycine utilises comme immonosuppresseurs
WO1996041807A1 (fr) 1995-06-09 1996-12-27 Novartis Ag Derives de rapamycine
WO1998002441A2 (fr) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathogènes
WO2001014387A1 (fr) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. Analogues d'epirapamycine-28
WO2006122806A2 (fr) 2005-05-20 2006-11-23 Novartis Ag Imidazoquinolines utilises en tant qu'inhibiteurs de kinase lipidique
WO2007084786A1 (fr) 2006-01-20 2007-07-26 Novartis Ag Derives de pyrimidine utilises en tant qu’inhibiteurs de kinase pi-3
WO2008103636A1 (fr) 2007-02-20 2008-08-28 Novartis Ag Imidazoquinoléines comme inhibiteurs doubles de kinase lipidique et de mtor
WO2009036082A2 (fr) 2007-09-12 2009-03-19 Genentech, Inc. Combinaisons de composés inhibiteurs des phosphoinositide 3-kinases et agents chimiothérapeutiques, et leurs procédés d'utilisation
WO2009055730A1 (fr) 2007-10-25 2009-04-30 Genentech, Inc. Procédé de préparation de composés de thiénopyrimidine
WO2012047775A1 (fr) * 2010-10-04 2012-04-12 Novartis Ag Combinaisons pharmaceutiques
WO2012075253A2 (fr) * 2010-12-03 2012-06-07 Novartis Ag Compositions pharmaceutiques

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005179A1 (fr) 1990-09-19 1992-04-02 American Home Products Corporation Esters d'acide carboxylique de rapamycine
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5120842B1 (fr) 1991-04-01 1993-07-06 A Failli Amedeo
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
WO1993011130A1 (fr) 1991-12-03 1993-06-10 Smithkline Beecham Plc Derive de rapamycine et son utilisation medicinale
WO1994002136A1 (fr) 1992-07-17 1994-02-03 Smithkline Beecham Corporation Derives de rapamycine
WO1994002485A1 (fr) 1992-07-17 1994-02-03 Smithkline Beecham Corporation Derives de rapamycine
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
WO1994009010A1 (fr) 1992-10-09 1994-04-28 Sandoz Ltd. Derives o-alkyles de la rapamycine et leur utilisation, en particulier comme immunosuppresseurs
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
WO1995014023A1 (fr) 1993-11-19 1995-05-26 Abbott Laboratories Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
WO1995016691A1 (fr) 1993-12-17 1995-06-22 Sandoz Ltd. Derives de rapamycine utilises comme immonosuppresseurs
WO1996041807A1 (fr) 1995-06-09 1996-12-27 Novartis Ag Derives de rapamycine
WO1998002441A2 (fr) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathogènes
WO2001014387A1 (fr) 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. Analogues d'epirapamycine-28
WO2006122806A2 (fr) 2005-05-20 2006-11-23 Novartis Ag Imidazoquinolines utilises en tant qu'inhibiteurs de kinase lipidique
WO2007084786A1 (fr) 2006-01-20 2007-07-26 Novartis Ag Derives de pyrimidine utilises en tant qu’inhibiteurs de kinase pi-3
WO2008103636A1 (fr) 2007-02-20 2008-08-28 Novartis Ag Imidazoquinoléines comme inhibiteurs doubles de kinase lipidique et de mtor
WO2009036082A2 (fr) 2007-09-12 2009-03-19 Genentech, Inc. Combinaisons de composés inhibiteurs des phosphoinositide 3-kinases et agents chimiothérapeutiques, et leurs procédés d'utilisation
WO2009055730A1 (fr) 2007-10-25 2009-04-30 Genentech, Inc. Procédé de préparation de composés de thiénopyrimidine
WO2012047775A1 (fr) * 2010-10-04 2012-04-12 Novartis Ag Combinaisons pharmaceutiques
WO2012075253A2 (fr) * 2010-12-03 2012-06-07 Novartis Ag Compositions pharmaceutiques

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BARAKAT, ENDOCRINE-RELATED CANCER, vol. 11, 2004, pages 1 - 18
DAVIS ET AL., GYNECOLOGY & OBSTETRICS, vol. 137, 1973, pages 637 - 644
HALFDANARSON ET AL., ANN ONCOL., vol. 19, no. 10, October 2008 (2008-10-01), pages 1727 - 33
HELLMAN ET AL.: "Principles and Practice of Oncology, 4th Edition", vol. 1, 1993, article "Principles of Radiation Therapy, Cancer", pages: 248 - 275
HOWLADER ET AL., J. NATL CANCER INST., vol. 102, no. 20, 20 October 2010 (2010-10-20), pages 1584 - 98
KULKE M., CANCER TREATMENT REVIEWS, vol. 29, 2003, pages 363 - 370
MODLIN IM ET AL., GASTROENTEROLOGY, vol. 128, 2005, pages 1717 - 1751
OBERG; JELIC, ANN. ONCOL., vol. 20, no. 4, May 2009 (2009-05-01), pages 150 - 3
THERASSE ET AL., J. NATL. CANCER INST., vol. 92, 2000, pages 205 - 216
TOMASSETTI, ANN ONCOL, vol. 12, no. 2, 2001, pages S95 - S99
YAO ET AL., J. CLIN. ONCOL., vol. 26, no. 18, 20 June 2008 (2008-06-20), pages 3063 - 72
ZITZMANN K ET AL: "Compensatory activation of Akt in response to mTOR and Raf inhibitors - A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease", CANCER LETTERS, NEW YORK, NY, US, vol. 295, no. 1, 1 September 2010 (2010-09-01), pages 100 - 109, XP027075305, ISSN: 0304-3835, [retrieved on 20100603], DOI: 10.1016/J.CANLET.2010.02.018 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10457679B2 (en) 2015-09-17 2019-10-29 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10882858B2 (en) 2015-09-17 2021-01-05 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US11613539B2 (en) 2015-09-17 2023-03-28 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2022106579A1 (fr) * 2020-11-20 2022-05-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composés pour traiter une maladie associée à la sénescence des macrophages
CN114209844A (zh) * 2022-01-27 2022-03-22 中以海德人工智能药物研发股份有限公司 一种用于治疗病毒性肝炎的药物组合物

Also Published As

Publication number Publication date
TW201402120A (zh) 2014-01-16

Similar Documents

Publication Publication Date Title
CA2736361C (fr) Combinaison d'un inhibiteur de la phosphatidylinositol-3-kinase (pi3k) et d'un inhibiteur de mtor
PT1615640E (pt) Combinações antineoplásticas
EP2892535B1 (fr) Procédé de traitement du cancer par adjuvant
AU2013271871A1 (en) Combination of a 17 -alpha -Hydroxylase (C17, 20 - lyase) inhibitor and a specific PI-3K inhibitor for treating a tumor disease
US20200281923A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
AU2011240001B2 (en) Combination of organic compounds
WO2013192367A1 (fr) Traitement d'une tumeur neuroendocrine
US20180353495A1 (en) Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
TW202300145A (zh) 藥物組合、包含其的試劑盒及其用途
WO2013152165A1 (fr) Méthodes de traitement du cancer à l'aide d'un inhibiteur de pi3k et d'un inhibiteur de mek
US11911374B2 (en) Methods and uses for treating cancer
US20230338325A1 (en) Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas
CN110121338A (zh) 脾酪氨酸激酶抑制剂和其他治疗剂的组合
TW202508598A (zh) 癌症療法
WO2018144791A1 (fr) Combinaison d'inhibiteurs de vps34 et d'inhibiteurs de mtor
OA17142A (en) Methods for treating cancer using PI3K inhibitor and MEK inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13737470

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13737470

Country of ref document: EP

Kind code of ref document: A1